Manipal Health

Manipal Health Enterprises Limited is a leading integrated healthcare provider in India, functioning as a key entity of the Manipal Group, which was established by T. M. A. Pai. The company has evolved into a powerhouse of medical services, focusing on delivering high-quality patient care and increasing healthcare accessibility across the country.

The business model revolves around a hub-and-spoke network of healthcare facilities. The company provides a vast array of specialized medical services, including cardiology, neurology, orthopaedics, oncology, and complex organ transplants, alongside preventive healthcare and diagnostic services.

In terms of operational scale, as of September 30, 2025, the company operates 38 hospitals, with a pro forma expansion to 48 hospitals. This network comprises 10,761 beds, which scales up to 12,367 licensed beds on a pro forma basis, complemented by 17 specialized clinics.

The company's market position is strengthened by its multi-specialty approach and extensive bed capacity, allowing it to serve a diverse patient base across various geographies in India. Its operations are designed to integrate primary care clinics with tertiary care hospitals.

The promoter group is led by Dr. Ranjan Ramdas Pai and includes entities such as Manipal Global Health Services, Memg International Ltd, Kangto Investments Pte. Ltd., Imperius Healthcare Investments Pte. Ltd., and Kabru Investments Pte. Ltd.

The Manipal Health Enterprises IPO is a mega-sized book-build issue seeking to raise approximately ₹9,273.64 Crores. The structure consists of a substantial fresh issue of ₹7,998.43 Crores and an Offer for Sale (OFS) of 2,16,13,834 equity shares. The price band is set between ₹560 and ₹590 per share, with a minimum retail lot size of 25 shares amounting to ₹14,750. The issue is scheduled to open on July 29, 2026, and close on July 31, 2026, with listing on the BSE and NSE on August 5, 2026.

Proceeds from the fresh issue are primarily earmarked for debt reduction, with ₹5,378 Crore allocated for the repayment or prepayment of outstanding borrowings and accrued interest of its material subsidiary, Manipal Hospitals Private Limited. Additionally, ₹574 Crore is intended for the acquisition of a minority stake in its step-down subsidiary, Sahyadri Hospitals Private Limited.

Financial performance shows a strong upward trajectory in revenue, growing from ₹6,265.17 Crores in FY24 to ₹10,520.52 Crores in FY2026. However, the Profit After Tax (PAT) exhibited inconsistency, peaking at ₹1,081.67 Crores in FY25 before declining to ₹916.52 Crores in FY26, despite the increase in top-line revenue.

Valuation-wise, the company reports a Basic EPS of ₹7.71 for FY2026. While specific P/E ratios are not provided in the dossier, comparisons with industry peers like Apollo Hospitals, Fortis, and Max Healthcare suggest a highly competitive landscape where these peers often trade at high multiples (66x to 74x).

Key strengths include a massive operational scale, a strong brand under the Manipal Group, and a high ROCE of 21.88%. Conversely, the primary risks include the recent dip in net profitability and the sheer size of the issue, which may lead to pricing volatility upon listing.

Overall, the IPO presents a mix of aggressive growth in revenue and a strategic move to deleverage the balance sheet. Investors may view this as a long-term play in the healthcare infrastructure space, though the immediate listing performance may be muted by the large float size.